Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives
Heart failure (HF) is the leading cause of death worldwide. The most effective HF treatment is heart transplantation, the use of which is restricted by the limited supply of donor hearts. The human pluripotent stem cell (hPSC), including human embryonic stem cell (hESC) and the induced pluripotent s...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/9/11/605 |
| _version_ | 1797469065733734400 |
|---|---|
| author | Junjun Li Li Liu Jingbo Zhang Xiang Qu Takuji Kawamura Shigeru Miyagawa Yoshiki Sawa |
| author_facet | Junjun Li Li Liu Jingbo Zhang Xiang Qu Takuji Kawamura Shigeru Miyagawa Yoshiki Sawa |
| author_sort | Junjun Li |
| collection | DOAJ |
| description | Heart failure (HF) is the leading cause of death worldwide. The most effective HF treatment is heart transplantation, the use of which is restricted by the limited supply of donor hearts. The human pluripotent stem cell (hPSC), including human embryonic stem cell (hESC) and the induced pluripotent stem cells (hiPSC), could be produced in an infinite manner and differentiated into cardiomyocytes (CMs) with high efficiency. The hPSC-CMs have, thus, offered a promising alternative for heart transplant. In this review, we introduce the tissue-engineering technologies for hPSC-CM, including the materials for cell culture and tissue formation, and the delivery means into the heart. The most recent progress in clinical application of hPSC-CMs is also introduced. In addition, the bottleneck limitations and future perspectives for clinical translation are further discussed. |
| first_indexed | 2024-03-09T19:16:11Z |
| format | Article |
| id | doaj.art-7a0e154a5cc1469195275d288fdd4ab7 |
| institution | Directory Open Access Journal |
| issn | 2306-5354 |
| language | English |
| last_indexed | 2024-03-09T19:16:11Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Bioengineering |
| spelling | doaj.art-7a0e154a5cc1469195275d288fdd4ab72023-11-24T03:45:56ZengMDPI AGBioengineering2306-53542022-10-0191160510.3390/bioengineering9110605Engineered Tissue for Cardiac Regeneration: Current Status and Future PerspectivesJunjun Li0Li Liu1Jingbo Zhang2Xiang Qu3Takuji Kawamura4Shigeru Miyagawa5Yoshiki Sawa6Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanCardiovascular Division, Osaka Police Hospital, Tennoji, Osaka 543-0035, JapanHeart failure (HF) is the leading cause of death worldwide. The most effective HF treatment is heart transplantation, the use of which is restricted by the limited supply of donor hearts. The human pluripotent stem cell (hPSC), including human embryonic stem cell (hESC) and the induced pluripotent stem cells (hiPSC), could be produced in an infinite manner and differentiated into cardiomyocytes (CMs) with high efficiency. The hPSC-CMs have, thus, offered a promising alternative for heart transplant. In this review, we introduce the tissue-engineering technologies for hPSC-CM, including the materials for cell culture and tissue formation, and the delivery means into the heart. The most recent progress in clinical application of hPSC-CMs is also introduced. In addition, the bottleneck limitations and future perspectives for clinical translation are further discussed.https://www.mdpi.com/2306-5354/9/11/605heart failurehuman induced pluripotent stem cellscardiac regenerationtissue engineeringcardiomyocytes |
| spellingShingle | Junjun Li Li Liu Jingbo Zhang Xiang Qu Takuji Kawamura Shigeru Miyagawa Yoshiki Sawa Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives Bioengineering heart failure human induced pluripotent stem cells cardiac regeneration tissue engineering cardiomyocytes |
| title | Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives |
| title_full | Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives |
| title_fullStr | Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives |
| title_full_unstemmed | Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives |
| title_short | Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives |
| title_sort | engineered tissue for cardiac regeneration current status and future perspectives |
| topic | heart failure human induced pluripotent stem cells cardiac regeneration tissue engineering cardiomyocytes |
| url | https://www.mdpi.com/2306-5354/9/11/605 |
| work_keys_str_mv | AT junjunli engineeredtissueforcardiacregenerationcurrentstatusandfutureperspectives AT liliu engineeredtissueforcardiacregenerationcurrentstatusandfutureperspectives AT jingbozhang engineeredtissueforcardiacregenerationcurrentstatusandfutureperspectives AT xiangqu engineeredtissueforcardiacregenerationcurrentstatusandfutureperspectives AT takujikawamura engineeredtissueforcardiacregenerationcurrentstatusandfutureperspectives AT shigerumiyagawa engineeredtissueforcardiacregenerationcurrentstatusandfutureperspectives AT yoshikisawa engineeredtissueforcardiacregenerationcurrentstatusandfutureperspectives |